Apoptotic pathway marker

Apoptotic pathway markers encompass a broad set of proteins and molecular signals that govern programmed cell death, a critical process for maintaining cellular homeostasis and eliminating damaged or redundant cells (Source: NIH, StatPearls). The pathway is primarily categorized into the intrinsic (mitochondrial) pathway, regulated by the B-cell lymphoma 2 (BCL-2) family, and the extrinsic (death receptor) pathway, initiated by extracellular ligands (Source: Nature Reviews Molecular Cell Biology). Key markers include caspases, which are cysteine proteases that execute the cell death program, and mitochondrial proteins like Cytochrome c (Source: PubMed). In oncology, the evasion of apoptosis is a hallmark of cancer, leading to the development of drugs like Venetoclax that inhibit anti-apoptotic proteins to restore the cell's ability to self-destruct (Source: FDA, Journal of Clinical Oncology). Beyond cancer, dysregulation of these markers is implicated in neurodegenerative disorders and autoimmune diseases, where excessive or insufficient apoptosis contributes to pathogenesis (Source: Cell Death & Disease). Therapeutic intervention often involves small molecules or antibodies designed to modulate these markers to either induce death in malignant cells or preserve survival in degenerating tissues (Source: British Journal of Pharmacology). Monitoring these markers, such as cleaved Caspase-3 or Annexin V staining, serves as a vital tool for assessing the efficacy of pro-apoptotic therapies in clinical and preclinical settings (Source: Journal of Biological Chemistry).

Other names

Programmed cell death markersApoptosis-related proteinsCell death markersApoptotic signaling molecules

Drugs targeting these markers typically function by either inhibiting anti-apoptotic proteins (e.g., BCL-2 inhibitors) to lower the threshold for cell death or by directly activating pro-apoptotic signaling cascades (e.g., TRAIL receptor agonists) to induce programmed cell death in diseased cells.